Published in Br J Cancer on February 01, 1998
Effects of the kava chalcone flavokawain A differ in bladder cancer cells with wild-type versus mutant p53. Cancer Prev Res (Phila) (2008) 1.34
Transcriptional Targeting in Cancer Gene Therapy. J Biomed Biotechnol (2003) 1.03
p22/WAF1 expression in human colorectal carcinoma: association with p53, transcription factor AP-2 and prognosis. Br J Cancer (1999) 0.95
Phosphatidylinositol 3'-kinase, mTOR, and glycogen synthase kinase-3β mediated regulation of p21 in human urothelial carcinoma cells. BMC Urol (2011) 0.88
Prognostic value of cell cycle regulatory proteins in muscle-infiltrating bladder cancer. J Cancer Res Clin Oncol (2006) 0.83
Decreased expression of p57(KIP2)mRNA in human bladder cancer. Br J Cancer (2000) 0.81
WAF1, a potential mediator of p53 tumor suppression. Cell (1993) 38.72
Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science (1995) 7.25
New functional activities for the p21 family of CDK inhibitors. Genes Dev (1997) 6.97
p53-independent expression of p21Cip1 in muscle and other terminally differentiating cells. Science (1995) 6.01
p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev (1995) 5.63
Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med (1994) 4.34
Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res (1995) 3.13
Involvement of the cell-cycle inhibitor Cip1/WAF1 and the E1A-associated p300 protein in terminal differentiation. Proc Natl Acad Sci U S A (1995) 2.70
The absence of p21Cip1/WAF1 alters keratinocyte growth and differentiation and promotes ras-tumor progression. Genes Dev (1996) 2.61
Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21. Oncogene (1994) 2.52
Functional analysis of the transforming growth factor beta responsive elements in the WAF1/Cip1/p21 promoter. J Biol Chem (1995) 2.35
Deletion of the p16 and p15 genes in human bladder tumors. J Natl Cancer Inst (1995) 2.25
Absence of WAF1 mutations in a variety of human malignancies. Blood (1994) 1.95
The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo. Nat Med (1995) 1.90
p53 mutations in human bladder cancer: genotypic versus phenotypic patterns. Int J Cancer (1994) 1.58
Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder. Br J Cancer (1991) 1.39
Loss of RB protein expression in primary bladder cancer correlates with loss of heterozygosity at the RB locus and tumor progression. Int J Cancer (1993) 1.06
p21 RNA and protein expression in non-small cell lung carcinomas: evidence of p53-independent expression and association with tumoral differentiation. Oncogene (1996) 1.05
The spectrum of TP53 mutations in bladder carcinoma. Genes Chromosomes Cancer (1994) 0.99
Somatic mutations of the WAF1/CIP1 gene in primary prostate cancer. Oncogene (1995) 0.93
p53 mutations and prognosis in bladder tumors. J Urol (1995) 0.91
Abrogation of apoptosis induced by DNA-damaging agents in human bladder-cancer cell lines with p21/WAF1/CIP1 and/or p53 gene alterations. Int J Cancer (1996) 0.91
Inactivation of tumor suppressor genes and deregulation of the c-myc gene in urothelial cancer cell lines. Urol Res (1995) 0.90
Comparison of P53 protein overexpression with P53 mutation in bladder cancer: clinical and biologic aspects. Lab Invest (1995) 0.88
Expression of p21WAF1/CIP1 is heterogeneous and unrelated to proliferation index in human ovarian carcinoma. Int J Cancer (1995) 0.88
Molecular analysis of the Cip1/Waf1 (p21) gene in diverse types of human tumors. Biochim Biophys Acta (1995) 0.87
Expression of c-myc protein is related to cell proliferation and expression of growth factor receptors in transitional cell bladder cancer. J Pathol (1995) 0.87
Low levels of expression of an inhibitor of cyclin-dependent kinases (CIP1/WAF1) in primary breast carcinomas with p53 mutations. Clin Cancer Res (1995) 0.85
Novel p21WAF1/CIP1 mutations in superficial and invasive transitional cell carcinomas. Oncogene (1996) 0.83
P53 accumulation in precursor lesions and early stages of bladder cancer. World J Urol (1994) 0.82
Correlation of morphometry, nucleolar organizer regions, proliferating cell nuclear antigen and Ki67 antigen expression with grading and staging in urinary bladder carcinomas. Br J Urol (1995) 0.81
IL-1 induces expression of WAF1 mRNA in human fibroblasts: mechanisms of accumulation. Biochem Biophys Res Commun (1995) 0.78
Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res (1999) 2.21
Improved diagnostic value of echocardiography in patients with infective endocarditis by transoesophageal approach. A prospective study. Eur Heart J (1988) 1.90
DNA methylation and expression of LINE-1 and HERV-K provirus sequences in urothelial and renal cell carcinomas. Br J Cancer (1999) 1.86
Tumor dedifferentiation: an important step in tumor invasion. Clin Exp Metastasis (1986) 1.54
Formation of 8-hydroxy(deoxy)guanosine and generation of strand breaks at guanine residues in DNA by singlet oxygen. Biochemistry (1991) 1.53
Differential subcellular localization of functionally divergent survivin splice variants. Cell Death Differ (2002) 1.50
Expression of different survivin variants in gastric carcinomas: first clues to a role of survivin-2B in tumour progression. Br J Cancer (2002) 1.45
Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation. Br J Cancer (2004) 1.41
High frequency of alterations in DNA methylation in adenocarcinoma of the prostate. Prostate (1999) 1.40
Dynamic expression pattern of the myc protooncogene in midgestation mouse embryos. Science (1989) 1.24
Hypomethylation of L1 LINE sequences prevailing in human urothelial carcinoma. Cancer Res (1996) 1.24
Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma. World J Urol (2011) 1.14
Increased frequency of a null-allele for NAD(P)H: quinone oxidoreductase in patients with urological malignancies. Pharmacogenetics (1997) 1.14
Enhancement of reporter gene de novo methylation by DNA fragments from the alpha-fetoprotein control region. J Biol Chem (1994) 1.13
Expression parameters of the polycomb group proteins BMI1, SUZ12, RING1 and CBX7 in urothelial carcinoma of the bladder and their prognostic relevance. Tumour Biol (2008) 1.12
Tiam1 mutations in human renal-cell carcinomas. Int J Cancer (2000) 1.12
Effects of WNT/beta-catenin pathway activation on signaling through T-cell factor and androgen receptor in prostate cancer cell lines. Int J Oncol (2005) 1.12
Concomitant down-regulation of SPRY1 and SPRY2 in prostate carcinoma. Endocr Relat Cancer (2006) 1.12
Incidence and prognostic significance of vascular invasion in 529 gastric-cancer patients. Int J Cancer (1991) 1.09
Staging of pelvic lymph nodes in neoplasms of the bladder and prostate by positron emission tomography with 2-[(18)F]-2-deoxy-D-glucose. Eur Urol (1999) 1.09
Morphological, immunohistochemical and biochemical characterization of 6 newly established human ovarian carcinoma cell lines. Int J Cancer (1992) 1.08
A comparative analysis of N-myc and c-myc expression and cellular proliferation in mouse organogenesis. Mech Dev (1991) 1.08
Establishment and characterization of four cell lines derived from human head and neck squamous cell carcinomas for an autologous tumor-fibroblast in vitro model. Anticancer Res (2000) 1.06
Delineation of the 6p22 amplification unit in urinary bladder carcinoma cell lines. Cancer Res (2000) 1.05
Transcriptional regulation of the human LINE-1 retrotransposon L1.2B. Mol Genet Genomics (2003) 1.04
Optimizing local anesthesia during 10-core biopsy of the prostate. Urology (2002) 1.04
Disturbed balance of expression between XIAP and Smac/DIABLO during tumour progression in renal cell carcinomas. Br J Cancer (2004) 1.04
Predictors for long-term survival after interdisciplinary salvage surgery for advanced or recurrent gynecologic cancers. J Surg Oncol (2007) 1.03
Fibroblast growth factors and their receptors in urological cancers: basic research and clinical implications. Eur Urol (2003) 1.01
Glutathione transferase isozyme genotypes in patients with prostate and bladder carcinoma. Arch Toxicol (2000) 1.01
E-cadherin involved in inactivation of WNT/beta-catenin signalling in urothelial carcinoma and normal urothelial cells. Br J Cancer (2003) 1.01
Expression of basic fibroblast growth factor in primary human renal tumors: correlation with poor survival. J Natl Cancer Inst (1993) 1.01
Lowered amounts of the tissue-specific transcription factor LFB1 (HNF1) correlate with decreased levels of glutathione S-transferase alpha messenger RNA in human renal cell carcinoma. Cancer Res (1994) 1.00
Expression of NAD(P)H:quinone oxidoreductase and glutathione S-transferases alpha and pi in human renal cell carcinoma and in kidney cancer-derived cell lines. Carcinogenesis (1994) 1.00
Perforated jejunal diverticulitis as a rare cause of acute abdomen. Eur Radiol (1999) 0.99
Differential effects of Nucleostemin suppression on cell cycle arrest and apoptosis in the bladder cancer cell lines 5637 and SW1710. Cell Prolif (2009) 0.97
Loss of heterozygosity at the NAD(P)H: quinone oxidoreductase locus associated with increased resistance against mitomycin C in a human bladder carcinoma cell line. Biol Chem Hoppe Seyler (1994) 0.95
DKC1 overexpression associated with prostate cancer progression. Br J Cancer (2009) 0.95
Destabilization of chromosome 9 in transitional cell carcinoma of the urinary bladder. Br J Cancer (2001) 0.95
Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan. Cell Death Differ (2000) 0.95
Disruption of the FA/BRCA pathway in bladder cancer. Cytogenet Genome Res (2007) 0.94
[Positron emission tomography with [18 F]-2-fluoro-2-deoxy-D-glucose (18FDG-PET) in diagnosis of retroperitoneal lymph node metastases of testicular tumors]. Urologe A (1998) 0.94
Differential characteristics of two new tumorigenic cell lines of human breast carcinoma origin. Int J Cancer (1998) 0.93
DNA methylation and the mechanisms of CDKN2A inactivation in transitional cell carcinoma of the urinary bladder. Lab Invest (2000) 0.93
Tumor-cell dissociation at the invasion front: a new prognostic parameter in gastric cancer patients. Int J Cancer (1992) 0.93
Apoptosis induction in renal cell carcinoma by TRAIL and gamma-radiation is impaired by deficient caspase-9 cleavage. Br J Cancer (2003) 0.92
Over-expression and amplification of the c-myc gene in human urothelial carcinoma. Int J Cancer (1999) 0.91
Terminal differentiation and growth inhibition of a rat rhabdomyosarcoma cell line (BA-HAN-1C) in vitro after exposure to retinoic acid. Cancer Res (1988) 0.90
Terminally differentiated postmitotic tumor cells in a rat rhabdomyosarcoma cell line. Virchows Arch B Cell Pathol Incl Mol Pathol (1988) 0.90
TRAIL-beta and TRAIL-gamma: two novel splice variants of the human TNF-related apoptosis-inducing ligand (TRAIL) without apoptotic potential. Br J Cancer (2003) 0.90
Inactivation of tumor suppressor genes and deregulation of the c-myc gene in urothelial cancer cell lines. Urol Res (1995) 0.90
Polymorphic methyl group metabolism genes in patients with transitional cell carcinoma of the urinary bladder. Mutat Res (2001) 0.90
Stem cells in the biology of normal urothelium and urothelial carcinoma. Neoplasma (2012) 0.89
Differential response to transforming growth factor (TGF)-alpha and fibroblast growth factor (FGF) in human renal cell carcinomas of the clear cell and papillary types. Eur J Cancer (2000) 0.89
Temporary remission of an alveolar rhabdomyosarcoma diagnosed and treated as acute leukemia. Leuk Lymphoma (2000) 0.89
Functional intactness of stimulatory and inhibitory autocrine loops in human renal carcinoma cell lines of the clear cell type. J Urol (1997) 0.88
Novel mutations of the von hippel-lindau tumor-suppressor gene and rare DNA hypermethylation in renal-cell carcinoma cell lines of the clear-cell type. Int J Cancer (2000) 0.88
Loss of HNF1alpha function in human renal cell carcinoma: frequent mutations in the VHL gene but not the HNF1alpha gene. Mol Carcinog (1999) 0.88
Retinoic acid induces myogenin synthesis and myogenic differentiation in the rat rhabdomyosarcoma cell line BA-Han-1C. J Cell Biol (1992) 0.87
Hypermethylation of the tumor necrosis factor receptor superfamily 6 (APT1, Fas, CD95/Apo-1) gene promoter at rel/nuclear factor kappaB sites in prostatic carcinoma. Mol Carcinog (2001) 0.87
[The early recurrence of Crohn's disease after "curative" ileocecal resection. A prospective endoscopic and histological study]. Dtsch Med Wochenschr (1990) 0.87
Multidrug resistance phenotype and paclitaxel (Taxol) sensitivity in human renal carcinoma cell lines of different histologic types. Cancer Invest (2000) 0.86
Sarcoma of the pulmonary artery: report of two cases and a review of the literature. J Cancer Res Clin Oncol (1992) 0.86
The androgen receptor in hormone-refractory prostate cancer: relevance of different mechanisms of androgen receptor signaling (Review). Int J Oncol (2003) 0.86
Interclonal heterogeneity in a human epithelioid-sarcoma cell line (GRU-1). Int J Cancer (1994) 0.86
Phenol sulphotransferase SULT1A1 polymorphism in prostate cancer: lack of association. Arch Toxicol (2000) 0.86
Growth inhibitory effects of paclitaxel on human epithelioid sarcoma in vitro: heterogeneity of response and the multidrug resistance phenotype. Cancer (2000) 0.85
Coexpression of the c-myc protooncogene with alpha-fetoprotein and albumin in fetal mouse liver. Differentiation (1990) 0.85
A comparative study of the in vitro antimicrobial activity of tea tree oils s.l. with special reference to the activity of beta-triketones. Planta Med (2000) 0.85
Methyl group metabolism gene polymorphisms and susceptibility to prostatic carcinoma. Prostate (2000) 0.85
Acute lethal necrotising pancreatitis in childhood systemic lupus erythematosus--possible toxicity of immunosuppressive therapy. Clin Exp Rheumatol (1995) 0.85
Predisposition towards urolithiasis associated with the NQO1 null-allele. Pharmacogenetics (1998) 0.85
Characterization of a human carcinosarcoma cell line of the ovary established after in vivo change of histologic differentiation. Gynecol Oncol (2001) 0.84
c-myc in bladder cancer. Clinical findings and analysis of mechanism. Urol Res (1997) 0.84
Neurogenic appendicopathy: a clinical disease entity? Int J Colorectal Dis (2002) 0.84
Placental Schistosoma haematobium infection in a German returnee from Malawi. Infection (2014) 0.84
Characterization of two newly established cell lines derived from squamous cell carcinomas of the oesophagus. Anticancer Res (1997) 0.83
Expression of heat shock protein 70 in renal cell carcinoma and its relation to tumor progression and prognosis. Histol Histopathol (2007) 0.83
Dexamethasone restores hormonal inducibility of ornithine decarboxylase in primary cultures of rat hepatocytes. Eur J Biochem (1985) 0.83
Novel survivin-related members of the inhibitor of apoptosis (IAP) family. Cell Death Differ (2000) 0.83
Living donor nephrectomy in an open technique; a long-term analysis of donor outcome. Transplant Proc (2003) 0.83
[Merkel cell tumor of the hand in a 104-year-old patient. Case report with review of the literature]. Handchir Mikrochir Plast Chir (1996) 0.83
In developing brown adipose tissue c-myc protooncogene expression is restricted to early differentiation stages. Cell Differ Dev (1989) 0.82
P53 accumulation in precursor lesions and early stages of bladder cancer. World J Urol (1994) 0.82
Deficient activation of CD95 (APO-1/Fas)-mediated apoptosis: a potential factor of multidrug resistance in human renal cell carcinoma. Br J Cancer (2000) 0.82
IFN-gamma-mediated coordinated transcriptional regulation of the human TAP-1 and LMP-2 genes in human renal cell carcinoma. Clin Cancer Res (1997) 0.82
Topotecan (Hycamtin) responsiveness in human renal carcinoma cell lines of the clear cell and papillary types. Anticancer Res (2002) 0.82
[Alveolar rhabdomyosarcoma presenting as acute leukemia]. Verh Dtsch Ges Pathol (1998) 0.81
Acquisition of TGF-beta 1 resistance: an important progression factor in human renal cell carcinoma. Lab Invest (1997) 0.81
Adjacent guanines as preferred sites for strand breaks in plasmid DNA irradiated with 193 nm and 248 nm UV laser light. J Photochem Photobiol B (1996) 0.81
FHIT expression in clear cell renal carcinomas: versatility of protein levels and correlation with survival. J Pathol (2002) 0.81